Foslevodopa/Foscarbidopa

How It Works

Foslevodopa/foscarbidopa (brand name Vyalev, previously known as Produodopa) is a subcutaneous infusion therapy consisting of prodrugs of levodopa and carbidopa delivered continuously through a small wearable pump. After subcutaneous absorption, foslevodopa is converted to levodopa and foscarbidopa is converted to carbidopa. The continuous 24-hour delivery produces steady-state plasma levodopa levels, virtually eliminating the peaks and troughs responsible for motor fluctuations in advanced Parkinson's disease. FDA approved October 2024, it is the first subcutaneous levodopa-based continuous therapy.

Typical Dosing

Continuous 24-hour subcutaneous infusion via wearable pump. Dose individualized based on prior oral levodopa dose using a conversion table. Infusion rate can be adjusted for daytime (higher, during waking hours) and nighttime (lower, during sleep). The pump and infusion set are changed by the patient or caregiver.

Dosing is individualized by the prescribing physician. The information above is for general reference only.

Common Side Effects

• Infusion site reactions (nodules, erythema, pain, edema — occur in most patients)
• Nausea
• Falls
• Hallucinations
• Infusion site discoloration

Serious Side Effects

Seek medical attention immediately if you experience any of the following:

• Infusion site infections
• Hallucinations and psychosis
• Impulse control disorders
• Orthostatic hypotension
• Device complications (pump malfunction, cannula dislodgement)
• Neuroleptic malignant syndrome on abrupt withdrawal

Contraindications

• Nonselective MAO inhibitors
• Known hypersensitivity to levodopa or carbidopa

Food Interactions

Continuous subcutaneous delivery bypasses GI absorption entirely, eliminating food interaction concerns including the protein-levodopa interaction that affects oral formulations. This is a significant advantage for patients who struggle with medication-meal timing.

Drug Interactions

The following interactions have been documented with Foslevodopa/Foscarbidopa. Always inform your healthcare provider about all medications you are taking.

How Foslevodopa/Foscarbidopa Compares to Alternatives

Vyalev competes directly with Duopa (intestinal levodopa gel infusion) and Onapgo (subcutaneous apomorphine infusion) for advanced PD motor fluctuation management. Compared to Duopa: Vyalev does NOT require surgical PEG-J tube placement — the subcutaneous cannula is inserted by the patient/caregiver, a major advantage in terms of invasiveness, infection risk, and reversibility. Both provide continuous levodopa delivery. Compared to Onapgo (apomorphine infusion): Vyalev uses the better-tolerated levodopa pathway while Onapgo acts directly on dopamine receptors. Onapgo causes more nausea and requires antiemetic pretreatment. Compared to DBS: Vyalev is reversible, does not require brain surgery, and can be started/stopped at any time — but DBS may provide superior motor outcomes for carefully selected patients.

When Is Foslevodopa/Foscarbidopa Used by Disease Stage?

Not used in early or mid-stage PD. Vyalev is specifically designed for advanced PD (Stages 3-5) with significant motor fluctuations that are not adequately controlled by optimized oral therapy. It is positioned as a less invasive alternative to Duopa for patients who need continuous levodopa delivery but want to avoid intestinal surgery. Candidates typically experience 2+ hours of daily off-time despite optimized oral medications. The treatment requires patients or caregivers who can manage the pump system and perform subcutaneous cannula insertion.

Additional Notes

First subcutaneous continuously delivered levodopa therapy. FDA approved October 2024 (brand name changed from Produodopa to Vyalev). Provides steady-state levodopa levels, reducing motor fluctuations without requiring intestinal surgery (unlike Duopa, which requires PEG-J tube placement). The phase 3 trial demonstrated significant reduction in off-time and increase in on-time without troublesome dyskinesia compared to oral immediate-release carbidopa/levodopa. The pump is worn externally and connected via a small subcutaneous cannula. Infusion site reactions are the most common adverse effect and occur in the majority of patients.